Employees: 35
Size Fennec Pharmaceuticals (FENC) is a United States Health Care company (Biotechnology) with a market value of $471M, the 2715th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.33 on 18 Nov 2026.
Performance Over six months the shares gained 36.7%, against -15.8% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 19 in its peer set.
Growth Revenue grew 71.1% over the last twelve months (peer median -4.3%); the operating margin is 4.9% (peer median -17.2%).
Valuation It trades at 16.9× forward earnings against a peer median of 21.5× (2nd cheapest of 6).
Price implies For today's price to make sense, revenue must grow about 59% a year for seven years (Req g). Recent delivered growth is +205%, so the hurdle is -146 pp: the price already allows for a slowdown.
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $66.4M | $44.6M | $47.5M | $21.3M | $1.53M |
| Revenue growth | — | -6% | +124% | +1,284% | — |
| Gross profit | $62.5M | $40.9M | $44.4M | $20.0M | $1.45M |
| EBITDA | $3.33M | -$6.28M | $2.57M | -$12.8M | -$22.6M |
| Net income | $1.67M | -$9.74M | -$436,000 | -$16.0M | -$23.7M |
| Free cash flow | $1.18M | -$14.4M | $27.0M | -$17.1M | -$18.1M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Total debt | $0 | $0 | $18.1M | $29.7M | $24.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FENC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +27.4% | -10.8% | highest of 21 |
| 6-month return | +36.7% | -15.8% | 3rd highest of 19 |
| Distance from 52-week high | -3.8% | -44.1% | highest of 21 |
| Revenue growth (TTM) | +71.1% | -4.3% | highest of 15 |
| Operating margin | 4.9% | -17.2% | 4th highest of 15 |
| Forward P/E | 16.9× | 21.5× | 2nd cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | 58.8% | 7.7% | most demanding of 4 |
| Growth delivered (Del g) | +204.7% | +7.0% | highest of 4 |
| Hurdle (Req g minus delivered) | -145.9 pp | +0.4 pp | least demanding of 4 |
| Net debt / EBITDA | -14.6× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 16.9× | 58.8% | +204.7% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 17.9× | 5.0% | +6.5% |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 2.3× | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | n/a | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | n/a | n/a | n/a |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | n/a | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | n/a | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 37.5× | n/a | n/a |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | n/a | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | n/a | 29.4% | +7.0% |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | n/a | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 21.5× | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | n/a | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 33.9× | 7.7% | +7.3% |